A Study to Evaluate the Safety and Tolerability of EXN407

The requested reference [a224c8513430b85d99b2386aafa1256eb7701514] no longer exists in our database. It has been replaced by the current reference: [c1535005781cdfdbaafd8812bfea846ae3029229]

Authors Exonate Limited -More
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2020
Links ClinicalTrials.gov
This first in human (FIH), Phase Ib/II study of EXN407 is a randomised, double-masked, vehicle-controlled, multiple dose, dose-escalating study to evaluate the safety and tolerability of EXN407 in subjects with centre involved Diabetic Macular Oedema (DMO), with Centre-subfield macular thickness (CMT) between 280-420 µm and Best corrected visual acuity (BCVA) better than or equal to 69 ETDRS score (approximate Snellen equivalent 20/40 (6/12 letters) in the study eye, which is considered secondary to diabetes mellitus. This study will provide a basis for further clinical development of EXN407 ophthalmic solution.
Epistemonikos ID: e7b9d1c4695ff01dfae9106b75696c649026c83f
First added on: Oct 02, 2023